The present invention provides a type I insulin-like growth factor receptor (IGF-1R) inhibitor comprising, as an active ingredient, an indazole derivative represented by Formula (I): ##STR00001## {wherein R.sup.1 represents --NR.sup.4R.sup.5 [wherein R.sup.4 represents a hydrogen atom or the like, R.sup.5 represents substituted or unsubstituted lower alkyl, --C(.dbd.O)R.sup.6 (wherein R.sup.6 represents substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl or the like), or the like], or the like, and R.sup.2 and R.sup.3 may be the same or different and each represents a hydrogen atom, hydroxy, substituted or unsubstituted lower alkoxy, or the like} or a pharmaceutically acceptable salt thereof, and the like.